STSaskia Tamminga

Saskia Tamminga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saskia Tamminga has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Lidewij Henneman

    Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands

    3 shared publications
  • Martina C. Cornel

    Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands

    3 shared publications
  • Merel van Maarle

    Academic Medical Centre, Amsterdam, the Netherlands

    2 shared publications
  • Caterina M. Bilardo

    Department of Fetal Medicine and Prenatal Diagnosis, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands

    1 shared publication
  • Cees B.M. Oudejans

    Department of Clinical chemistry, VU University Medical Center, Amsterdam, the Netherlands

    1 shared publication
  • E. J. ( Joanne) Verweij

    Department of Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    What do people want to know about NIPT? Content analysis of questions emailed to national NIPT information websites

    by Saskia Tamminga, Laura van Dussen, E. J. ( Joanne) Verweij, Marjon A. de Boer, Martina C. Cornel, Lidewij Henneman, for the Dutch NIPT Consortium

    What's already known about this topic? Several countries, including the Netherlands, have implemented non‐invasive prenatal testing (NIPT) in their national prenatal screening program Access to relevant online health information is important as it increases informed decision making What does this study add? Visitors of national NIPT websites mostly request more information about testing beyond the currently available NIPT: a broader range of disorders (such as monogenic disorders) and increasing target group eligibility (such as low‐risk or twin pregnancies) © 2017 The Authors. Prenatal Diagnosis published by John Wiley & Sons, Ltd.


  • Maternal Plasma DNA and RNA Sequencing for Prenatal Testing

    by Saskia Tamminga, Merel van Maarle, Lidewij Henneman, Cees B.M. Oudejans, Martina C. Cornel, Erik A. Sistermans


  • Open Access

    Changing to NIPT as a first-tier screening test and future perspectives: opinions of health professionals

    by Saskia Tamminga, Rachèl V. van Schendel, Wieke Rommers, Caterina M. Bilardo, Eva Pajkrt, Wybo J. Dondorp, Merel van Maarle, Martina C. Cornel, Lidewij Henneman

    Objective The aim of this study was to investigate health professionals' opinions toward offering noninvasive prenatal testing (NIPT) as first-tier screening test regardless of pregnant women's risk, and toward a potential broader range of disorders. Methods A questionnaire completed by obstetric health professionals (n = 240) after an in-service NIPT training in the West and North of the Netherlands. Results The majority (72%) of respondents favored replacing first-trimester combined test (FCT) by NIPT, although 43% preferred to maintain nuchal translucency measurement. Many respondents believed that replacing FCT by NIPT would only have advantages (57%), would lead to more pregnant women opting for prenatal testing (69%), and would simplify counseling (47%). Differences in attitudes toward counseling between health professionals were observed. When considering NIPT to screen for broader range of disorders, the majority (92%) thought that this should include disorders characterized by neonatal death, whereas 52% of the respondents favored testing for fetomaternal risk factors. Overall, 46% thought screening should be offered as a fixed list of disorders. Conclusion Most health professionals favor NIPT instead of FCT but prefer to maintain nuchal translucency measurement. If NIPT becomes available as a first-tier screening test, attention remains necessary to ensure that pregnant women make well-informed decisions in line with the aim of prenatal screening. © 2015 John Wiley & Sons, Ltd.